Quantum-Si (NASDAQ:QSI) and MaxCyte (NASDAQ:MXCT) Head-To-Head Review

MaxCyte (NASDAQ:MXCT) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares MaxCyte and Quantum-Si”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03 million	4.47	-$44.63 million	($0.33)	-4.33
Quantum-Si	$2.44 million	104.06	-$101.34 million	($0.46)	-2.52

MaxCyte has higher revenue and earnings than Quantum-Si. MaxCyte is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for MaxCyte and Quantum-Si, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1	1	1	0	2.00
Quantum-Si	1	1	2	0	2.25

MaxCyte currently has a consensus target price of $5.00, suggesting a potential upside of 249.65%. Quantum-Si has a consensus target price of $2.50, suggesting a potential upside of 115.52%. Given MaxCyte’s higher possible upside, research analysts plainly believe MaxCyte is more favorable than Quantum-Si.

Profitability

This table compares MaxCyte and Quantum-Si’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

Risk and Volatility

MaxCyte has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 3.21, indicating that its share price is 221% more volatile than the S&P 500.

Institutional & Insider Ownership

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 22.0% of Quantum-Si shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MaxCyte beats Quantum-Si on 8 of the 13 factors compared between the two stocks.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

About Quantum-Si

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.